Zhou JY - Search Results

1

[The effect of silicon dioxide on the activation of nuclear factor-kappaB in THP-1 cells].

Zhou JY, Mao GG, Tang FD, Zhou JY. Zhou JY, et al. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2003 Jun;21(3):179-81. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2003. PMID: 14761478 Chinese.

2

Inhibitory effect of 1,8-cineol (eucalyptol) on Egr-1 expression in lipopolysaccharide-stimulated THP-1 cells.

Zhou JY, Wang XF, Tang FD, Zhou JY, Lu GH, Wang Y, Bian RL. Zhou JY, et al. Acta Pharmacol Sin. 2007 Jun;28(6):908-12. doi: 10.1111/j.1745-7254.2007.00555.x. Acta Pharmacol Sin. 2007. PMID: 17506951

3

[hVEGF siRNA inhibits initial growth of A549 tumor cells in nude mice and angiogenesis on CAM assay].

Liu R, Ma WJ, Zhou JY, Yang GD, Zhou JY. Liu R, et al. Among authors: zhou jy. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2009 Mar;38(2):136-44. doi: 10.3785/j.issn.1008-9292.2009.02.004. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2009. PMID: 19363820 Chinese.

4

Sesquiterpene lactone parthenolide markedly enhances sensitivity of human A549 cells to low-dose oxaliplatin via inhibition of NF-kappaB activation and induction of apoptosis.

Fang LJ, Shao XT, Wang S, Lu GH, Xu T, Zhou JY. Fang LJ, et al. Among authors: zhou jy. Planta Med. 2010 Feb;76(3):258-64. doi: 10.1055/s-0029-1186083. Epub 2009 Sep 11. Planta Med. 2010. PMID: 19774508

5

Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors.

Zhao Q, Shentu J, Xu N, Zhou J, Yang G, Yao Y, Tan F, Liu D, Wang Y, Zhou J. Zhao Q, et al. Lung Cancer. 2011 Aug;73(2):195-202. doi: 10.1016/j.lungcan.2010.11.007. Epub 2010 Dec 8. Lung Cancer. 2011. PMID: 21144613 Clinical Trial.

6

Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells.

Chen X, Zhou JY, Zhao J, Chen JJ, Ma SN, Zhou JY. Chen X, et al. Among authors: zhou jy. Anticancer Drugs. 2013 Nov;24(10):1039-46. doi: 10.1097/CAD.0000000000000011. Anticancer Drugs. 2013. PMID: 23962905

7

MicroRNA-34a: role in cancer and cardiovascular disease.

Chen X, Zhou JY, Zhou JY. Chen X, et al. Among authors: zhou jy. Curr Drug Targets. 2014 Apr;15(4):361-73. doi: 10.2174/1389450115666140120102935. Curr Drug Targets. 2014. PMID: 24438466 Review.

8

Accurate and economical detection of ALK positive lung adenocarcinoma with semiquantitative immunohistochemical screening.

Zhou J, Zhao J, Sun K, Wang B, Wang L, Chen X, Zheng J, You Q, Wang X, Ding W, Zhou J. Zhou J, et al. PLoS One. 2014 Mar 25;9(3):e92828. doi: 10.1371/journal.pone.0092828. eCollection 2014. PLoS One. 2014. PMID: 24667320 Free PMC article. Clinical Trial.

9

[Molecular testing clinical progress for EGFR mutation and ALK rearrangement of lung cancer based on the guideline from IASLC/CAP/AMP].

Zhou J, Zhou J. Zhou J, et al. Zhonghua Jie He He Hu Xi Za Zhi. 2014 Mar;37(3):167-9. Zhonghua Jie He He Hu Xi Za Zhi. 2014. PMID: 24809706 Chinese. No abstract available.

10

MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET.

Zhou JY, Chen X, Zhao J, Bao Z, Chen X, Zhang P, Liu ZF, Zhou JY. Zhou JY, et al. Cancer Lett. 2014 Sep 1;351(2):265-71. doi: 10.1016/j.canlet.2014.06.010. Epub 2014 Jun 28. Cancer Lett. 2014. PMID: 24983493

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,244 results

Search Page

Filters